Therapeutic Asset Ratings

394 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sacituzumab Tirumotecan Primary Peritoneal Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (54)
Solu-Cortef Metastatic Prostate Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (54)
Capecitabine Ovarian Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (54)
LENVATINIB Cholangiocarcinoma	Merck Sharp & Dohme LLC	P2	CCC (54)
LENVATINIB Ovarian Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (54)
Pembrolizumab/Vibostolimab Coformulation Cholangiocarcinoma	Merck Sharp & Dohme LLC	P2	CCC (54)
Pembrolizumab/Vibostolimab Coformulation Ovarian Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (54)
Benadryl Advanced Biliary Cancer	Merck Sharp & Dohme LLC	P1/2	CCC (54)
mk-1045 Follicular Lymphoma	Merck Sharp & Dohme LLC	P2/3	CCC (54)
Belzutifan Gastrointestinal Stromal Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Belzutifan HIF-2α Mutated Cancers	Merck Sharp & Dohme LLC	P2	CCC (53)
Belzutifan Pancreatic Neuroendocrine Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Benadryl Lung Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (53)
Cyclophosphamide Carcinoid Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Cyclophosphamide Parotid Gland Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Cyclophosphamide Salivary Gland Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Cyclophosphamide Thyroid Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Epirubicin Carcinoid Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Epirubicin Parotid Gland Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Epirubicin Salivary Gland Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Epirubicin Thyroid Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Epirubicin Vulvar Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Epirubicin Vulvar Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
FLUDROCORTISONE Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Classical Hodgkin Lymphoma Recurrent	Merck Sharp & Dohme LLC	P2	CCC (53)

Showing 201 to 225 of 394 assets

PreviousPage 9 of 16Next